Literature DB >> 22743723

Advanced glycation end product accumulation in the cardiomyocytes of heart failure patients with and without diabetes.

Jerzy Nożyński1, Michał Zakliczyński, Dominika Konecka-Mrowka, Teresa Zielinska, Helena Zakliczynska, Barbara Nikiel, Joanna Mlynarczyk-Liszka, Andrzej Mrowka, Ewa Zembala-Nozynska, Marta Pijet, Kinga Rdzanowska, Dariusz Lange, Roman Przybylski, Marian Zembala.   

Abstract

BACKGROUND: Non-enzymatic coupling of protein and lipid cellular structures with glucose leading to the formation of advanced glycation end products (AGE) plays a role in aging and the development of diabetic complications, but its contribution to myocardial pathology is unclear. We aimed to assess the role of heart failure on AGE formation in patients with or without diabetes mellitus type 2 (DM2). MATERIAL/
METHODS: Heart tissue specimens from 136 patients undergoing transplantation were grouped as follows: 14 cases of ischemic cardiomyopathy (ICM) and DM2, 8 cases of dilated cardiomyopathy (DCM) and DM2, 67 cases of ICM without DM2, and 47 cases of DCM without DM2. Fourteen heart samples were from the autopsies of patients with DM2 without heart disease, and 20 heart samples were from organ donors in whom the heart was wasted. AGE deposits were localized immunohistochemically counted using a semiquantitative scale and characterized by their staining pattern.
RESULTS: Positive staining was present in all samples from both cardiomyopathy groups with DM2, in 71% of healthy hearts from the DM2 subjects, in 51% of ICM non-diabetic hearts, and in 38% of DCM non-diabetic hearts, and in only 15% of the organ donors. Mixed-diffuse and granular AGE patterns were characteristic for DM2, while a diffuse pattern was more frequently observed in heart failure patients without diabetes. The semiquantitative results supported increased AGE accumulation in patients with DM2 and/or cardiomyopathy.
CONCLUSIONS: The amount of AGE in cardiomyocytes increases significantly in both diabetes and heart failure, with a staining pattern typical for each condition.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22743723     DOI: 10.12659/aot.883223

Source DB:  PubMed          Journal:  Ann Transplant        ISSN: 1425-9524            Impact factor:   1.530


  14 in total

Review 1.  Implication of advanced glycation end products (Ages) and their receptor (Rage) on myocardial contractile and mitochondrial functions.

Authors:  Remi Neviere; Yichi Yu; Lei Wang; Frederic Tessier; Eric Boulanger
Journal:  Glycoconj J       Date:  2016-06-08       Impact factor: 2.916

2.  Myocardial native-T1 times are elevated as a function of hypertrophy, HbA1c, and heart rate in diabetic adults without diffuse fibrosis.

Authors:  Bonnie Lam; Tori A Stromp; Zhengxiong Hui; Moriel Vandsburger
Journal:  Magn Reson Imaging       Date:  2019-05-21       Impact factor: 2.546

3.  Advanced Glycation End Products: Building on the Concept of the "Common Soil" in Metabolic Disease.

Authors:  Henry H Ruiz; Ravichandran Ramasamy; Ann Marie Schmidt
Journal:  Endocrinology       Date:  2020-01-01       Impact factor: 4.736

Review 4.  Interrelationship between diabetes mellitus and heart failure: the role of peroxisome proliferator-activated receptors in left ventricle performance.

Authors:  Evangelos Oikonomou; Konstantinos Mourouzis; Petros Fountoulakis; Georgios Angelos Papamikroulis; Gerasimos Siasos; Alexis Antonopoulos; Georgia Vogiatzi; Sotiris Tsalamadris; Manolis Vavuranakis; Dimitris Tousoulis
Journal:  Heart Fail Rev       Date:  2018-05       Impact factor: 4.214

Review 5.  Advanced glycation end products: role in pathology of diabetic cardiomyopathy.

Authors:  Vijaya Lakshmi Bodiga; Sasidhar Reddy Eda; Sreedhar Bodiga
Journal:  Heart Fail Rev       Date:  2014-01       Impact factor: 4.214

6.  Ramipril inhibits AGE-RAGE-induced matrix metalloproteinase-2 activation in experimental diabetic nephropathy.

Authors:  Kei Fukami; Sho-Ichi Yamagishi; Melinda T Coughlan; Brooke E Harcourt; Phillip Kantharidis; Vicki Thallas-Bonke; Seiya Okuda; Mark E Cooper; Josephine M Forbes
Journal:  Diabetol Metab Syndr       Date:  2014-08-13       Impact factor: 3.320

7.  Evolution and bad prognostic value of advanced glycation end products after acute heart failure: relation with body composition.

Authors:  Beatriz Paradela-Dobarro; Ángel Fernández-Trasancos; Diana Bou-Teen; Sonia Eiras; Rocío González-Ferreiro; Rosa M Agra; Alfonso Varela-Román; Ana I Castro-Pais; Marcos C Carreira; Felipe F Casanueva; Ezequiel Álvarez; José R González-Juanatey
Journal:  Cardiovasc Diabetol       Date:  2017-09-15       Impact factor: 9.951

8.  DNA aptamer raised against AGEs blocks the progression of experimental diabetic nephropathy.

Authors:  Yusuke Kaida; Kei Fukami; Takanori Matsui; Yuichiro Higashimoto; Yuri Nishino; Nana Obara; Yosuke Nakayama; Ryotaro Ando; Maki Toyonaga; Seiji Ueda; Masayoshi Takeuchi; Hiroyoshi Inoue; Seiya Okuda; Sho-ichi Yamagishi
Journal:  Diabetes       Date:  2013-04-29       Impact factor: 9.461

9.  Esculin improves dyslipidemia, inflammation and renal damage in streptozotocin-induced diabetic rats.

Authors:  Yue-Hua Wang; Yan-Hong Liu; Guo-Rong He; Yang Lv; Guan-Hua Du
Journal:  BMC Complement Altern Med       Date:  2015-11-09       Impact factor: 3.659

10.  Abundance, localization, and functional correlates of the advanced glycation end-product carboxymethyl lysine in human myocardium.

Authors:  Martin M LeWinter; Douglas Taatjes; Takamaru Ashikaga; Bradley Palmer; Nicole Bishop; Peter VanBuren; Stephen Bell; Cameron Donaldson; Markus Meyer; Kenneth B Margulies; Margaret Redfield; David A Bull; Michael Zile
Journal:  Physiol Rep       Date:  2017-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.